Ballicules.com

Ciclopirox

LOPROX

Pronunciation: sye-kloe-PEER-ox

Ciclopirox ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Ciclopirox ballicule

What it isHydroxypyridone antifungal chelating polyvalent cations; onychomycosis and tinea.

Why this oneTopical, so it avoids the hepatotoxicity and interactions of oral terbinafine or itraconazole.

What limits itCure rates in onychomycosis are low and it takes up to 48 weeks of daily lacquer application.

Ciclopirox molecular structure (skeletal formula)
Molecular structure: Ciclopirox

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Tinea (pedis/cruris/corporis), candidiasis, tinea versicolorAdultsApply BID (morning and evening)Apply BID

Renal Undefined

Hepatic Undefined

Instructions

Available strengths

Cautions

Adverse reactions

Pregnancy Undefined

Lactation Undefined

Cost

Ciclopirox (LOPROX)
Strength#/mogeneric $/unitCostPlus
0.77 %suspper unitnot offered
0.77 %creamper unitnot offered
1 %shampooper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Ciclopirox is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2004

NO BOXED WARNINGS

Principal riskLow cure rate after 48 weeks of application

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityHepatotoxicity and clinically important CYP/QT interactions; organ toxicity varies markedly by agent.

Open Ciclopirox in the interactive console ↗